Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study - Hellmann, Matthew D; Rizvi, Naiyer A; Goldman, Jonathan W; Gettinger, Scott N; Borghaei, Hossein; Brahmer, Julie R; Ready, Neal E; Gerber, David E; Chow, Laura Q; Juergens, Rosalyn A; Shepherd, Frances A; Laurie, Scott A; et al. (The lancet oncology, 2017)
Keywords: Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Aged; Antibodies, Monoclonal - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - pathology; Chemotherapy; Cohort Studies; Female; Follow-Up Studies; Hematology; Hematology, Oncology and Palliative Medicine; Humans; Immunotherapy; Ipilimumab; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Melanoma; Metastasis; Middle Aged; Neoplasm Staging; Nivolumab; Pneumoviridae; Prognosis; Survival Rate